title: Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
authors.forename: Stefania
authors.initials: S
authors.lastname: Mariani
authors.forename: Lucia
authors.initials: L
authors.lastname: Tornaghi
authors.forename: Marianna
authors.initials: M
authors.lastname: Sassone
authors.forename: Sabrina
authors.initials: S
authors.lastname: Basciani
authors.forename: Raffaella
authors.initials: R
authors.lastname: Buzzetti
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Spera
authors.forename: Lucio
authors.initials: L
authors.lastname: Gnessi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001786:Blood Glucose / Q000032:analysis*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate